Hepatic Reactions During Treatment of Multiple Sclerosis with Interferon- -1a: Incidence and Clinical Significance

ISSN： 0114-5916

Source： Drug Safety, Vol.26, Iss.11, 2003-01, pp. : 815-827

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon-β_1b for the treatment of multiple sclerosis

By Lam Sum Wang Shan Gottesman Malcolm

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 8, 2008-08 ,pp. : 1111-1117

Informa Healthcare

Access to resources Recommend Favorite

Interferon-β_1b in the treatment of multiple sclerosis

By Río Jordi Montalban Xavier

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2877-2886

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of Serum Levels of Chemokines during Interferon-β Treatment in Multiple Sclerosis Patients: A 1-Year, Observational Cohort Study

By Comini-Frota Elizabeth R.

CNS Drugs, Vol. 25, Iss. 11, 2011-11 ,pp. : 971-981

Adis International

Access to resources Recommend Favorite

Interferon-Beta in the Treatment of Multiple Sclerosis: Do Clinical Data Support the Existence of a Ceiling Effect?

By Clanet M.

Clinical Drug Investigation, Vol. 21, Iss. 4, 2001-04 ,pp. : 307-318

Adis International

Access to resources Recommend Favorite

Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a: Modelling the Clinical and Economic Implications

By Guo Shien Bozkaya Duygu

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 39-53

Adis International

Access to resources Recommend Favorite